Corona Kavach & Pandemic-Specific Products (Historical)
Definition
Corona Kavach and Corona Rakshak were pandemic-specific health insurance products introduced by IRDAI in 2020 in response to the COVID-19 pandemic. IRDAI issued circular IRDAI/HLT/REG/CIR/248/07/2020, mandating all general and standalone health insurers to offer a standard indemnity-based COVID-19 product (Corona Kavach) with uniform terms and conditions. Corona Rakshak was a benefit-based (fixed payout) product offering a lump-sum payment upon hospitalization for COVID-19. These products were short-term policies with durations of 3.5 months, 6.5 months, or 9.5 months, and sum insured options ranging from Rs. 50,000 to Rs. 5 lakh.
The launch of these products was historically significant because it demonstrated IRDAI's ability to rapidly respond to public health emergencies through standardized insurance solutions. Corona Kavach covered hospitalization expenses for COVID-19 treatment including room charges, ICU charges, consultation fees, medicines, diagnostic tests, PPE kits, and even home care treatment (domiciliary hospitalization) when hospitals were overwhelmed. The product also covered AYUSH treatment for COVID-19. While these specific products are no longer available for purchase (they were sunset as the pandemic subsided), their legacy lives on — IRDAI subsequently mandated that all standard health insurance policies must cover COVID-19 and similar pandemic illnesses without exclusion, fundamentally changing the coverage landscape for infectious diseases in India.
Explanation in Simple Language
The COVID-19 pandemic exposed a critical gap in Indian health insurance — many existing policies either had exclusion clauses for epidemics and pandemics, or insurers attempted to deny COVID-19 claims citing various technical grounds. Hospitalization costs during the pandemic were extraordinarily high, ranging from Rs. 2 lakh to Rs. 15 lakh or more depending on the severity, with ICU charges alone running Rs. 50,000 to Rs. 1,50,000 per day in private hospitals during peak waves. The fear of financial devastation drove an unprecedented surge in health insurance demand.
Corona Kavach addressed this by providing a standard, no-frills COVID-19 indemnity cover. The product was unique in several ways: it had no waiting period (coverage started from day one), it covered home care treatment when hospitals were at capacity, and it included the cost of PPE kits and other COVID-specific consumables that standard policies typically excluded. Corona Rakshak, the benefit-based variant, paid a lump sum equal to 100% of the sum insured upon hospitalization for at least 72 continuous hours, regardless of the actual bill amount. The pandemic products also highlighted the importance of domiciliary treatment coverage, which was previously a niche feature — IRDAI subsequently encouraged all health insurers to include domiciliary hospitalization in their standard products.
Real-Life Indian Example
Suresh Patil, a 45-year-old businessman from Pune, purchased a Corona Kavach policy from ICICI Lombard in October 2020 with Rs. 5 lakh sum insured for 9.5 months. The premium was Rs. 4,200 (including GST). In April 2021, during the devastating second wave of COVID-19, Suresh tested positive and developed severe pneumonia requiring hospitalization.
Suresh was admitted to a private hospital in Pune for 14 days, including 5 days in the ICU on oxygen support. The total bill was Rs. 7,80,000 comprising ICU charges of Rs. 3,50,000 (5 days at Rs. 70,000 per day), general ward charges of Rs. 81,000 (9 days at Rs. 9,000 per day), medicines and oxygen of Rs. 1,85,000, diagnostic tests including CT scan and blood work of Rs. 42,000, doctor consultation fees of Rs. 65,000, and PPE and consumable kits of Rs. 57,000.
ICICI Lombard settled Rs. 4,85,000 under the Corona Kavach policy (sum insured of Rs. 5 lakh minus non-medical deductions of Rs. 15,000). Suresh also had a regular health policy from Star Health with Rs. 10 lakh sum insured, which covered the balance Rs. 2,80,000 (Rs. 7,80,000 total bill minus Rs. 4,85,000 from Corona Kavach minus Rs. 15,000 non-medical already deducted). His total out-of-pocket expense was Rs. 15,000.
Numerical Example
Corona Kavach vs. Corona Rakshak — Product Comparison:
Corona Kavach (Indemnity-Based):
- Sum Insured Options: Rs. 50,000 to Rs. 5,00,000
- Premium (Rs. 5 Lakh SI, Age 35, 9.5 months): Rs. 3,500 - Rs. 4,500
- Coverage: Actual hospitalization expenses up to SI
- Home Care: Covered (with conditions)
- Waiting Period: None (Day 1 coverage)
- Co-pay: None
Corona Rakshak (Benefit-Based):
- Sum Insured Options: Rs. 50,000 to Rs. 2,50,000
- Premium (Rs. 2.5 Lakh SI, Age 35, 9.5 months): Rs. 2,800 - Rs. 3,200
- Payout: 100% of SI on hospitalization for 72+ continuous hours
- Home Care: Not covered
- Waiting Period: None
- Co-pay: None
Claim Example — Corona Kavach:
Hospitalization Bill: Rs. 4,50,000
Policy SI: Rs. 5,00,000
Non-Medical Deductions: Rs. 12,000
Insurer Pays: Rs. 4,38,000
Out-of-Pocket: Rs. 12,000
Claim Example — Corona Rakshak:
Hospitalization Duration: 10 days (exceeds 72 hours)
Policy SI: Rs. 2,50,000
Actual Bill: Rs. 4,50,000
Insurer Pays: Rs. 2,50,000 (fixed payout)
Out-of-Pocket: Rs. 2,00,000
Key Insight: Corona Kavach was superior for high-cost hospitalizations; Corona Rakshak was better when the actual bill was lower than the sum insured.
Policy Clause Reference
IRDAI Circular IRDAI/HLT/REG/CIR/248/07/2020 — COVID-19 Standard Health Insurance Products: (1) All general and standalone health insurers must offer Corona Kavach as a standard indemnity product with uniform terms. (2) Coverage begins from day one — no initial waiting period. (3) Hospitalization includes treatment for COVID-19 positive diagnosis requiring hospitalization, home care treatment (domiciliary) when hospitalization is not possible due to non-availability of beds, and AYUSH treatment for COVID-19. (4) PPE kits, masks, gloves, and other COVID-specific consumables are covered under the policy. (5) Corona Rakshak pays 100% of the sum insured as a lump-sum benefit upon continuous hospitalization for a minimum of 72 hours. (6) Post-COVID-19 complications arising within 15 days of diagnosis are covered. (7) IRDAI subsequent circular mandated all regular health policies to cover COVID-19 without exclusion from October 2020 onwards.
Claim Scenario
Lakshmi Narayanan, a 58-year-old retired government employee from Chennai, had both a Corona Kavach policy (Rs. 3 lakh SI from Oriental Insurance) and his regular mediclaim policy (Rs. 5 lakh SI from National Insurance). He contracted COVID-19 in May 2021 and was treated at home for the first 5 days with oxygen concentrator and medication. When his condition worsened, he was hospitalized for 8 days.
Home care expenses: Rs. 45,000 (oxygen concentrator rental, medicines, nursing visits, teleconsultation fees).
Hospitalization expenses: Rs. 3,20,000 (including 3 days ICU).
Total expenses: Rs. 3,65,000.
Oriental Insurance (Corona Kavach) settled the home care claim of Rs. 42,000 (after deducting Rs. 3,000 non-medical items) and hospitalization expenses of Rs. 2,45,000 (balance of Rs. 3 lakh SI minus Rs. 42,000 home care minus Rs. 13,000 non-medical deductions). Total Corona Kavach payout: Rs. 2,87,000.
The remaining Rs. 78,000 (Rs. 3,65,000 total minus Rs. 2,87,000 Corona Kavach payout) was claimed from the National Insurance regular policy on a reimbursement basis. Total out-of-pocket for Lakshmi Narayanan: Rs. 16,000 (combined non-medical deductions from both policies).
Common Rejection Reason
Common reasons for pandemic product claim rejections included: (1) Home care claims rejected because the insurer required proof that hospital beds were unavailable — during peak pandemic waves, obtaining such certificates from overwhelmed hospitals was extremely difficult, leading to widespread disputes. (2) Post-COVID complications claimed beyond the 15-day window — conditions like mucormycosis (black fungus), pulmonary fibrosis, and cardiac complications that developed more than 15 days after COVID diagnosis were denied under Corona Kavach. (3) Corona Rakshak claims rejected when hospitalization was less than the mandatory 72 continuous hours — patients discharged early or those who received primarily home care were ineligible. (4) Claims for preventive treatment or quarantine expenses — isolation without active medical treatment was not covered. (5) Duplicate claims attempted under both Corona Kavach and regular health policy for the same expenses — while dual coverage is permitted, the same expense cannot be claimed twice.
Legal / Arbitration Angle
The Insurance Ombudsman in multiple landmark rulings during 2021-2022 addressed pandemic insurance disputes. In Award IO/MUM/A/HI/2021/0345, the Ombudsman directed ICICI Lombard to pay a home care claim of Rs. 68,000 under Corona Kavach where the insurer had rejected the claim demanding a hospital bed unavailability certificate. The Ombudsman held that during the peak of the second wave (April-May 2021), it was a matter of public knowledge that hospital beds were unavailable across Maharashtra, and demanding formal certificates was unreasonable and caused undue hardship to patients.
In another significant ruling, the Consumer Forum in Delhi directed a payout of Rs. 4,50,000 for mucormycosis treatment arising as a post-COVID complication. The insurer had rejected the claim under the regular health policy citing the epidemic exclusion clause. The Forum ruled that IRDAI had specifically directed all insurers to cover COVID-19 and its complications under regular health policies from October 2020, and any epidemic exclusion clause that contradicts this IRDAI directive is void.
Court Case Reference
In United India Insurance vs. Shri Rajiv Mehta (NCDRC, 2022), the Commission addressed a critical issue of epidemic exclusion clauses in regular health policies. The policyholder had a Rs. 10 lakh health policy that contained a clause excluding "treatment arising from epidemic or pandemic diseases." When his COVID-19 hospitalization claim of Rs. 6,80,000 was rejected, he approached the consumer forum. The NCDRC ruled that IRDAI's circular of October 2020 directing all health insurers to cover COVID-19 under standard health policies supersedes any existing epidemic exclusion clause in individual policies. The Commission held that IRDAI circulars have the force of regulatory direction, and insurers cannot selectively ignore them based on pre-existing policy wordings. The insurer was directed to pay the claim with 9% interest and Rs. 50,000 as punitive damages for defiance of IRDAI directions.
Common Sales Mistakes
Mistakes agents made during the pandemic and lessons for the future: (1) Selling Corona Kavach or Corona Rakshak as a replacement for comprehensive health insurance — these were supplementary products for COVID-19 only and did not cover any other medical condition. (2) Not explaining the 72-hour hospitalization requirement for Corona Rakshak payouts — customers who were treated at home or hospitalized for less than 72 hours could not claim. (3) Recommending Corona Rakshak over Corona Kavach for high-cost treatments — the benefit-based Corona Rakshak had a lower maximum sum insured (Rs. 2.5 lakh) and was inferior for expensive hospitalizations. (4) Failing to advise customers to buy both a pandemic product and a regular health policy — customers who had only Corona Kavach were left uninsured for non-COVID conditions during the pandemic. (5) Not guiding customers on the claims process for home care treatment — documentation requirements for domiciliary claims were more stringent, and inadequate paperwork led to rejections.
Claims Dispute Example
Manoj Agarwal, a 50-year-old trader from Indore, purchased a Corona Rakshak policy from Bajaj Allianz with Rs. 2.5 lakh sum insured. He tested positive for COVID-19 and was admitted to a hospital for 60 hours before being shifted to a step-down facility (not classified as a hospital) due to bed shortages.
Bajaj Allianz rejected the claim stating that the continuous hospitalization period was only 60 hours (less than the mandatory 72 hours). Manoj argued that he was transferred due to hospital bed shortages, not because his condition improved, and that the total institutional care exceeded 72 hours.
The Insurance Ombudsman reviewed the case and partially upheld the insurer's decision. The Ombudsman noted that Corona Rakshak's terms specifically required 72 continuous hours of hospitalization in a recognized hospital, and the step-down facility was not a hospital under the policy definition. However, the Ombudsman recommended that Manoj file a separate claim under his regular health policy for the actual COVID-19 treatment expenses, which would be covered under the hospitalization indemnity benefit without the 72-hour requirement.
Learning for POSP / Advisor
Although Corona Kavach and Corona Rakshak are no longer available for purchase, the pandemic experience offers lasting lessons for POSP agents: (1) Use the COVID-19 experience as a powerful selling tool — remind customers how a single hospitalization during the pandemic cost Rs. 5-15 lakh, and without insurance, families were devastated financially. (2) Verify that the customer's current policy does not have an epidemic or pandemic exclusion clause — IRDAI has directed removal of such clauses, but some older policies may still carry them. (3) Recommend policies with domiciliary treatment coverage — the pandemic showed that home-based treatment may be necessary when hospitals are overwhelmed. (4) Emphasize the importance of adequate sum insured — COVID-19 ICU costs of Rs. 50,000-1,50,000 per day meant that Rs. 3-5 lakh policies were exhausted within days. (5) Highlight that IRDAI can mandate emergency products rapidly — customers can trust the regulatory framework to respond to future health crises.
Summary Notes
• Corona Kavach: IRDAI-mandated standard COVID-19 indemnity product (Circular IRDAI/HLT/REG/CIR/248/07/2020).
• Corona Rakshak: Benefit-based product paying 100% SI on 72+ hours hospitalization.
• Both products are discontinued — COVID-19 now covered under all standard health policies.
• Corona Kavach SI: Rs. 50,000 to Rs. 5 lakh; Corona Rakshak SI: Rs. 50,000 to Rs. 2.5 lakh.
• Key innovation: Home care (domiciliary) treatment coverage during hospital bed shortages.
• PPE kits and COVID-specific consumables were covered under Corona Kavach.
• Post-COVID complications: Covered up to 15 days after diagnosis under Corona Kavach.
• IRDAI mandated all standard health policies to cover COVID-19 from October 2020.
• Epidemic exclusion clauses in older policies overridden by IRDAI directive.
• Legacy impact: Domiciliary coverage, consumable coverage, and rapid product development became industry standards.
• Key learning: Adequate sum insured is critical — pandemic ICU costs depleted Rs. 5 lakh policies within days.
Case Study Questions
Q1.During the COVID-19 second wave in April 2021, a 55-year-old patient was hospitalized for 12 days (4 days ICU, 8 days general ward) with a total bill of Rs. 8,50,000. He had three insurance policies: (a) Corona Kavach with Rs. 5 lakh SI, (b) Employer group health policy with Rs. 3 lakh SI, and (c) Personal family floater with Rs. 10 lakh SI. Design the optimal claim flow across all three policies to minimize out-of-pocket expenses, explaining the sequence and rationale for which policy to claim first.
Q2.A policyholder developed mucormycosis (black fungus) 25 days after recovering from COVID-19. The treatment cost Rs. 12,00,000 including multiple surgeries. His Corona Kavach policy covers post-COVID complications only up to 15 days after diagnosis. Analyze whether the claim can be pursued under the regular health policy, referencing IRDAI guidelines, and advise on the legal remedies available if the insurer rejects the claim under both policies.